Nama's AI scorecard currently rates Viridian Therapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does VRDN report earnings?

Viridian Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.95.

What is the VRDN price target?

The median analyst price target from 15 analysts is $35.00, with a range of $22.00 – $50.00.

Is VRDN Shariah compliant?

Nama's AAOIFI-style screen reads Viridian Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Viridian Therapeutics (VRDN)

Healthcare · Biotechnology · NASDAQ

Viridian Therapeutics (VRDN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.24B and a free-cash-flow yield of -9.4%. Over the most recent reported fiscal year, revenue grew 23359.9%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -33.5% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-26.9%

How far the last close sits under the highest price of the past five years.

Market cap	$3.24B
Trailing P/E	—
Price / book	4.9
Price / sales	45.2
FCF yield	-9.4%
Dividend yield	—
Gross margin	0.0%
Operating margin	-44460.6%
Net margin	0.0%
Revenue growth (YoY)	+23359.9%
Revenue growth (3-yr annual)	+241.9%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

VRDN earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.95). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.81	-$1.02	+20.6%	$25.75M
Q2 2026	Aug 6, 2026	-$1.05	-$1.03	-1.9%	$284,000
Q1 2026	May 5, 2026	-$0.90	-$1.08	+16.7%	$141,000
Q4 2025	Feb 26, 2026	-$1.08	-$1.00	-8.0%	$132,000

VRDN analyst price target

Median target $35.00 from 15 analysts, ranging $22.00 – $50.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live VRDN data on Nama Insights →

VRDN FAQ

Is VRDN a buy?: Nama's AI scorecard currently rates Viridian Therapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does VRDN report earnings?: Viridian Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.95.
What is the VRDN price target?: The median analyst price target from 15 analysts is $35.00, with a range of $22.00 – $50.00.
Is VRDN Shariah compliant?: Nama's AAOIFI-style screen reads Viridian Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.